Search results for Lacnotuzumab

Lacnotuzumab Biosimilar – Anti-CSF1, MCSF mAb – Research Grade, ProteoGenix, PX-TA1466

Description of Lacnotuzumab Biosimilar - Anti-CSF1, MCSF mAb - Research Grade The Structure of Lacnotuzumab Biosimilar – Anti-CSF1, MCSF mAb Lacnotuzumab Biosimilar, also known as Anti-CSF1, MCSF mAb, is a monoclonal antibody that specifically targets the colony stimulating factor 1 (CSF1) protein. This protein plays a critical role in regulating the growth, differentiation, and survival of macrophages, a type of white blood cell involved in immune response and tissue repair. The structure of Lacnotuzumab Biosimilar is composed of two identical heavy chains and two identical light chains, each with a specific amino acid sequence. These chains are connected by disulfide bonds, forming a Y-shaped molecule with two antigen-binding sites. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains contain two constant domains (CL) and one variable domain (VL). The variable domains of Lacnotuzumab Biosimilar are responsible for its high specificity and affinity for the CSF1 protein. The antigen-binding sites on the tips of the Y-shaped molecule are able to recognize and bind to specific regions on the CSF1 protein, effectively blocking its activity. The Activity of Lacnotuzumab Biosimilar Lacnotuzumab Biosimilar is a potent inhibitor of CSF1, as it blocks the interaction between CSF1 and its receptor on the surface of macrophages. This prevents the activation of downstream signaling pathways that are necessary for macrophage survival, proliferation, and differentiation. By inhibiting CSF1, Lacnotuzumab Biosimilar can modulate the activity of macrophages in various physiological and pathological conditions. For example, in cancer, macrophages are known to promote tumor growth and metastasis. By targeting CSF1, Lacnotuzumab Biosimilar can disrupt the tumor-promoting activity of macrophages, potentially slowing down the progression of cancer. Furthermore, CSF1 is also involved in the regulation of bone metabolism. By blocking its activity, Lacnotuzumab Biosimilar can potentially be used to treat diseases such as osteoporosis and rheumatoid arthritis, where excessive bone resorption by macrophages is a contributing factor. The Application of Lacnotuzumab Biosimilar Lacnotuzumab Biosimilar is currently being developed as a therapeutic agent for various diseases, including cancer and bone disorders. It is being studied in preclinical and clinical trials to evaluate its safety and efficacy in these conditions. In cancer, Lacnotuzumab Biosimilar has shown promising results in preclinical studies, demonstrating its ability to inhibit tumor growth and metastasis. Clinical trials are underway to evaluate its efficacy in various types of cancer, including breast cancer, lung cancer, and melanoma. In bone disorders, Lacnotuzumab Biosimilar has shown potential in preclinical studies to prevent bone loss and promote bone formation. Clinical trials are currently ongoing to evaluate its effectiveness in treating osteoporosis and rheumatoid arthritis. In addition to its therapeutic potential, Lacnotuzumab Biosimilar is also being used as a research tool to study the role of CSF1 in various diseases and to develop new treatments targeting this protein. The Future of Lacnotuzumab Biosimilar Lacnotuzumab Biosimilar has shown promising results in preclinical and early clinical studies, and its potential as a therapeutic agent for cancer and bone disorders is being further explored. As more research is conducted, it is expected that the use of this antibody will expand to other diseases where CSF1 plays a critical role. Furthermore, the development of Lacnotuzumab Biosimilar also highlights the importance of targeting specific proteins and pathways in disease treatment. With the advancement of biotechnology and the understanding of disease mechanisms, more targeted therapies like Lacnotuzumab Biosimilar are likely to be developed in the future, providing more effective and personalized treatment options for patients.

Lacnotuzumab, Abbexa, abx831424

Lacnotuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CSF1/MCSF, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Lacnotuzumab ELISA Kit, ProteoGenix, KPTX165

Description of Lacnotuzumab ELISA Kit Introduction to Lacnotuzumab ELISA Kit A Powerful Tool for Detecting and Quantifying Lacnotuzumab and its Therapeutic Applications Introduction: Lacnotuzumab, also known as LY3012207, is a humanized monoclonal antibody that specifically targets the programmed death-ligand 1 (PD-L1) protein. PD-L1 is a cell surface protein that is expressed on various types of cancer cells and is responsible for suppressing the immune response against these cancer cells. Lacnotuzumab is currently being investigated as a potential therapeutic agent for various types of cancer, including lung cancer, head and neck cancer, and bladder cancer. In order to facilitate research and development of Lacnotuzumab, a highly sensitive and specific tool, the Lacnotuzumab ELISA Kit, has been developed. Structure of Lacnotuzumab ELISA Kit The Lacnotuzumab ELISA Kit is a sandwich enzyme-linked immunosorbent assay (ELISA) that utilizes a specific antibody for the detection and quantification of Lacnotuzumab. The kit consists of a 96-well microplate coated with a capture antibody that specifically binds to Lacnotuzumab. The sample, which can be serum, plasma, or cell culture supernatant, is added to the wells and incubated, allowing Lacnotuzumab to bind to the capture antibody. After washing away any unbound substances, a detection antibody, labeled with an enzyme, is added to the wells. This detection antibody binds to a different epitope on Lacnotuzumab, forming a sandwich complex. The amount of Lacnotuzumab present in the sample is then measured by adding a substrate that reacts with the enzyme and produces a color change, which can be quantified using a spectrophotometer. Activity of Lacnotuzumab ELISA Kit The Lacnotuzumab ELISA Kit has a high sensitivity and specificity for Lacnotuzumab, with a detection limit of 0.1 ng/mL. This means that even small amounts of Lacnotuzumab can be accurately detected and quantified. The kit also has a wide dynamic range, allowing for the measurement of Lacnotuzumab at different concentrations. Additionally, the Lacnotuzumab ELISA Kit has been validated for use with various sample types, making it a versatile tool for researchers. Title: Applications of Lacnotuzumab ELISA Kit The Lacnotuzumab ELISA Kit has numerous applications in the field of cancer research. It can be used to measure the levels of Lacnotuzumab in patient samples, providing valuable information for monitoring treatment response and predicting patient outcomes. The kit can also be used to screen for potential responders to Lacnotuzumab therapy, as it can detect even low levels of the antibody in patient samples. Furthermore, the Lacnotuzumab ELISA Kit can be used in preclinical studies to assess the pharmacokinetics and pharmacodynamics of Lacnotuzumab. This information is crucial for the development of dosing regimens and treatment strategies for Lacnotuzumab. In addition to its applications in cancer research, the Lacnotuzumab ELISA Kit can also be used in basic research to study the expression and regulation of PD-L1 in various cell types and tissues. This can help in understanding the role of PD-L1 in cancer development and progression. Conclusion: In conclusion, the Lacnotuzumab ELISA Kit is a powerful tool for detecting and quantifying Lacnotuzumab in various sample types. Its high sensitivity, specificity, and wide dynamic range make it an essential tool for cancer research and drug development. With the increasing interest in Lacnotuzumab as a potential therapeutic agent, the Lacnotuzumab ELISA Kit will continue to play a crucial role in advancing our understanding of this promising antibody and its potential in cancer treatment.

Lacnotuzumab ELISA Kit, Abbexa, abx395054

Lacnotuzumab ELISA Kit is a quantitative ELISA kit for detection of Lacnotuzumab.Lacnotuzumab, as known as MCS110, is a novel, high-affinity, humanized, anti-CSF-1 monoclonal antibody that prevents CSF-1 from activating the CSF-1R. The drug is being developed by Novartis Europharm Limited. On 15 October 2014, orphan designation (EU/3/14/1350) was granted by the European Commission to Novartis for recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor for the treatment of tenosynovial giant cell tumor, localized and diffuse type. They conducted a phase 1 study to assess the safety and tolerability of administering single ascending doses and repeat doses of lacnotuzumab to healthy volunteers, and to examine the pharmacokinetics (PK), pharmacodynamics (PD), and mechanistic properties of lacnotuzumab. Nonclinical investigations of the mechanism of action of lacnotuzumab were also performed to explain the observed adverse events (AEs) profile associated with CSF-1 pathway inhibition. Lacnotuzumab was generally well tolerated. The majority of AEs were low grade, no unexpected or novel AEs were observed, and there were no discontinuations for AEs. Lacnotuzumab also showed dose-dependent, on-target effects on multiple downstream biomarkers. Preclinical investigations of the CK elevation and periorbital swelling observed after lacnotuzumab administration suggest that these are reversible, nonpathological events linked to inhibition of the CSF-1 pathway. These data support further evaluation of lacnotuzumab in clinical studies.

Lacnotuzumab Biosimilar - Research Grade, ichor.bio, ICH5618

Research Grade Lacnotuzumab (HY515016), abinScience, HY515016